Korean Patients with Superwarfarin Intoxication and Their Outcome

This observational study aimed at evaluating recent superwarfarin intoxication of Korean patients. Ten patients were diagnosed as or highly suspicious for superwarfarin intoxication. Case report forms described by attending hematologists of the patients were collected and analyzed. Bleeding symptoms were varied among the patients. Patients uniformly showed prolonged prothrombin time (PT) and activated thromboplastin time (aPTT) with decreased activity of vitamin K dependent coagulation factors. Positive serum brodifacoum test results in 4 of 5 requested patients contributed to confirmatory diagnosis. Psychiatric interview revealed an attempted ingestion in one patient. High dose vitamin K1 therapy promptly corrected prolonged PT and aPTT, but hasty discontinuation caused repeated bleeding diathesis in 6 patients. Route of intoxication was unknown or not definite among 8 of 10 patients. Three patients had a possibility of environmental exposure considering their occupations: there might be intoxication by transdermal absorption or inhalation. Therefore, high dose and prolonged use of vitamin K1 therapy is necessary for effective detoxification. Further detailed investigation on environmental exposure and efforts to improve availability of the blood level test in clinic are requested.

**Key Words:** Superwarfarin; Brodifacoum; Vitamin K; Rodenticides

**INTRODUCTION**

Attempted or accidental superwarfarin exposure has become an important public problem in Western countries (1), as intoxication can cause prolonged bleeding diathesis, and sometimes fatal results. Over 10,000 cases of superwarfarin intoxication were reported in 2008 to the Poison Control Centers Toxic Exposure Surveillance System in the United States (2). In Korea, only sporadic reports of superwarfarin intoxication exist without any systemic and detailed investigations to the issue (3-5). We conducted an observational study of 10 cases of superwarfarin intoxication in Korea, most of them broke out within a year.

**MATERIALS AND METHODS**

Case report forms (CRF) for patients with superwarfarin intoxication were requested to 8 physicians from October 2009 to April 2010 by electronic mails. Each of the physicians was an attending hematologist of the patients. A CRF contained filling up section for basic information of a patient: age, sex, residence, occupation...
patation, past history of disease, and medication history of anticoagulants or anti-platelet agents, etc. Manifestations of bleeding were surveyed and initial laboratory data including prothrombin time (PT) and activated partial thromboplastin time (aPTT) were collected. Results of plasma mixing test, activity of coagulation factors and serum brodifacoum level test were also recorded. Flow-sheet of treatment and change of laboratory data including PT and aPTT of each patient were gathered. The CRFs were analyzed by Hong J and Bang S-M and the results were reviewed by the other authors.

Ethics statement
This study was performed for the public good and had neither risk nor disadvantage for subjects. Therefore, the institutional Review Board of Seoul National Hospital Bundang Hospital permitted this study without acquisition of informed consent (Approval number: B-1007-106-105).

RESULTS

Patient characteristics, symptoms and diagnoses
Seven male patients and 3 female patients were reported in this survey. Their age ranged 37-83. Only one patient (patient 6) lived in a metropolitan city, and outbreaks were nationwide. Most of the cases occurred since 2009, except for a male patient who diagnosed in 2007 (4). Two of them have been previously published as a case report (4, 5).

Reported bleeding events were oral mucosal bleeding (7 patients), hematuria (4 patients), easy bruising (5 patients), hematoma formation (5 patients), and epistaxis (3 patients).

Patients uniformly showed prolonged PT and aPTT with decreased activity of vitamin K dependent coagulation factors. Plasma mixing test and activities of coagulation factors were evaluated in all of the patients and the same result were showed: correction of PT and aPTT and decreased activities of factors II, VII, IX, and X. Serum brodifacoum test were requested in 5 of 10 patients by physicians and 4 of them with a positive result were definitely diagnosed as superwarfarin intoxication. One patient (patient 2) repeatedly denied any contact with rodenticides, but she confessed to trying to kill herself by taking rodenticides after an interview with a psychiatrist. One patient (patient 3) was initially witnessed ingestion of rodenticides by her neighbors so serum brodifacoum test was not performed.

Environmental exposure was a possible cause in 3 patients

| Patient ID | Age/sex | Regions | Presentation | Studies (seconds) | (Possible) origin of superwarfarin exposure | Superwarfarin level test |
|------------|---------|---------|--------------|------------------|---------------------------------------------|-------------------------|
| Patient 1  | Male/51 | Pohang-si Gyeongsangbuk-do | Oral mucosal bleeding Hematuria | PT>110 aPTT>240 | Unknown (history of blackout after alcohol drinking) | Positive result |
| Patient 2  | Female/37 | Imsil-gun Jeollabuk-do | Oral mucosal bleeding Epistaxis Intramuscular Hematoma | PT 89.4 aPTT 48.6 | Intentionally for suicidal attempt (confessed after psychiatric interview) | Negative result |
| Patient 3  | Female/80 | Jeonju-si Jeollabuk-do | Oral mucosal bleeding Ecchymosis Easy bruising | PT 52.3 aPTT 60.0 | Intentionally for suicidal attempt | Not done (taking rodenticide was witnessed by others) |
| Patient 4  | Male/43 | Hanam-si Gyeonggi-do | Hematoma collection | PT 117.9 aPTT 87.5 | Environ. Possibility; A horticulturist | Positive result |
| Patient 5 (5) | Male/52 | Yangju-si Gyeonggi-do | Epistaxis Hematuria Easy bruising Conjunctival hemorrhage Hemoptoneum | PT 50.7 aPTT 87.8 | Unknown (ingested fluconazole for suicidal attempt and ingestion of other drugs cannot be ruled out) | Positive result |
| Patient 6  | Male/45 | Seoul | Oral mucosal bleeding Ecchymosis Easy bruising | PT no clotting aPTT 124.3 | Unknown | Not done 7-OH warfarin test was negative |
| Patient 7  | Male/75 | Masan-si Gyeongsangnam-do | Oral mucosal bleeding Gluteal hematoma | PT 96.4 aPTT 96.4 | Environ. Possibility; used rodenticide at his grain warehouse | Not done |
| Patient 8  | Male/75 | Goryeong-gun Gyeongsangbuk-do | Epistaxis Oral mucosal bleeding Hematuria Ecchymosis Easy bruising | PT >100 aPTT 137.6 | Unknown | Not done |
| Patient 9  | Female/83 | Goryeong-gun Gyeongsangbuk-do | Oral mucosal bleeding Ecchymosis Easy bruising Hematoma collection | PT 36.6 aPTT 131 | Unknown | Not done |
| Patient 10 (4) | Male/58 | Chungcheongbuk-do | Hematuria | PT 165 aPTT 107 | Environ. Possibility; A ragman | Positive result |

PT, prothrombin time; aPTT, activated thromboplastin time; Environ., environmental.
(patients 4, 7, and 10) as they worked as a horticulturist, farmer, and ragman, respectively. Information for patient characteristics, symptoms and diagnoses were summarized in Table 1.

**Treatment**

Four patients (patient 1, 3, 4, and 6) failed to achieve sufficient correction of PT and aPTT initially so they had to increase doses of vitamin K1 administration. Repeated prolongation of PT and aPTT due to hasty discontinuation was observed in 6 patients (patient 1, 2, 3, 4, 6, and 8). FFP was initially transfused to all of the patients, but repeated FFP transfusion with low doses of vitamin K1 failed to maintain normalization of PT and aPTT in 4 patients (patient 1, 3, 4, and 6).

Durations of treatment were varied among the patients. Three patients (patient 1, 4, and 6) were completely discontinued vitamin K1 treatment, and their duration of vitamin K1 administration was 7.3, 6.2, and 3.3 months, respectively.

All of the patients recovered or are on recovering from PT and aPTT prolongation without sequelae and there was no mortality. Only a patient (patient 5) received major surgical procedure, evacuation of hemoperitoneum. He confessed that he ingested excessive amount of fluconazole, an anti fungal agent, but repeatedly denied superwarfarin ingestion even positive result of brodifacoum level test was reported. It seems to be that he needed operation because of potentiated action of brodifacoum by drug interactions with the fluconazole.

Information of treatment and state of recovery were summarized in Table 2.

**DISCUSSION**

The discovery of warfarin dates back to outbreaks of cattle death in the northern United States and Canada in the 1920s (6). After isolation of the hemorrhagic compound in moldy silage which led to the death of the cattle, first generation anticoagulants including warfarin were introduced. Warfarin is now widely used as a therapeutic anticoagulant, but its use as a rodenticide has declined because many rat populations have developed resistance to it (6).

To overcome this resistance, second generation anticoagulants, superfwarfarins were invented in the 1970s: brodifacoum and bromadiolone. They are highly lipid soluble and about 100 times more potent than warfarin because of the phenyl groups replacing the terminal methyl group in the structure (7). In a

---

### Table 2. Treatment outcomes in our series and four others from the literature

| Patients (Ref.) | Vitamin K1 treatment | Duration (months) | Recovery |
|----------------|----------------------|------------------|----------|
| Patient 1      | 10 mg IV q.d. intermittenly→poor response→60 mg IV q.d. for a day→90 mg IV q.d. for a day→120 mg IV q.d. for 2 days→100 mg q.d. PO for 4 months→tapered for 3 months | 7.3     | Recovered without sequelae |
| Patient 2      | 40 mg PO/day for a month→30 mg PO/day for 3 months→20 mg PO/day for a month→30 mg PO/day for 2 months→20 mg PO/day for a month→keep on therapy | >10     | On recovering |
| Patient 3      | 30 mg PO/day for a week→poor response→60 mg PO/day for a month→40 mg PO/day for a month→30 mg PO/day for 3 months→15 mg PO/day for 3 months→10 mg PO/day for a month→keep on therapy | >7.7    | On recovering |
| Patient 4      | 10 mg IV q.d. or 15 mg PO q.d. for 3.5 months→poor response→30 mg PO/day for 12 days→poor response→60 mg PO/day for about 6 months→negative for follow up brodifacoum level→stop therapy | 6.2     | Recovered without sequelae |
| Patient 5 (5)  | 200 mg PO/day for 5 days with surgical drainage of hemoperitoneum→10 mg/day for 2 months→transfer to other hospital then F/U* loss | >3.6    | On recovering |
| Patient 6      | 10 mg IV q.d. for 10 days→poor response→50 mg IV twice a week or 100 mg IM on the day IV was not performed for 5 weeks→50 mg IV once a week for a month→stop therapy | 3.3     | Recovered without sequelae |
| Patient 7      | 10 mg IV bid for 5 days→15 mg IV bid for 3 weeks→F/U loss | 1.0     | Once recovered, then F/U loss |
| Patient 8      | 30 mg IV/day for 5 days→30 mg PO/day for 7 days→60 mg PO/day for 60 days→keep on therapy | >2.2    | On recovering |
| Patient 9      | 30 mg IV/day for 4 days→10 mg IV/day for 5 days→10 mg PO/day for 14 days→keep on therapy | >0.8    | On recovering |
| Patient 10 (4) | 10 mg IV once for a week→5 mg PO q.d. for 2 months and a week→stop therapy | >2.6    | Recovered without sequelae |
| Bruno et al. (19) | 150 mg PO q.d. for 5 days→periodic tapering over the next 40 days | 1.5     | Recovered without sequelae |
| Pavlu et al. (14) | 10 mg IV q.i.d. for 3 days→no response→100 mg PO q.d. for 7 days→30 mg PO for 77 days→F/U loss | 2.9     | Once recovered, then F/U loss |
| Zupancic-Salek et al. (17) | 40 mg PO q.d. for 3 months→20 mg PO q.d. for 1 months→10 mg PO q.d. for 1 months→stop therapy | 5.0     | Recovered |
| Hui et al. (11) | 100 mg IV q.d. for 2 weeks→50 mg IV q.d. for 1 week→50 mg PO q.d. (Further treatment duration is not stated) | Not stated | Died 6 months after treatment |

*F/U, follow up.
field test, 1-2 days feeding of brodifacoum was sufficient to achieve complete mortality in most of rodent species, compared to 21 days of warfarin (8). The reported half life of brodifacoum in humans is much longer than that of warfarin (16-36 days vs 17-37 hr) (9).

The most common clinical feature of superwarfarin intoxication is bleeding, and this can occur from any mucosal site or organ. Various symptoms of bleeding were reported in the literatures (1, 3, 4, 9-17) as in our study.

Superwarfarin intoxication should be suspected in any patient who presents with a suspicious history and marked prolongation of both PT and aPTT without advanced liver disease or congenital coagulation factor deficiency. Mixing studies result in complete correction of PT and aPTT due to lack of inhibitors. Measuring the activity of vitamin K dependent coagulation factors (Factor II, VII, IX, and X), plasma vitamin K levels, or PIVKA-II can be helpful in narrowing down the differential diagnosis. The definitive diagnosis is made by superwarfarin blood level testing with high performance liquid chromatography (HPLC) an accurate and effective way of determining the presence and concentration of superwarfarin. Recent advances in HPLC technology has made considerably accurate and rapid diagnosis possible (18), but such technology is not yet easily accessible in Korea. In our study, although one patient (patient 2) was highly suspicious for superwarfarin intoxication and she even confessed ingestion, a negative result was reported. Weitzel et al. (9) evaluated half-life of brodifacoum in 3 patients with superwarfarin intoxication by measuring serial serum brodifacoum concentrations. They reported the half-life ranged from 16 to 36 days in 3 patients and serum brodifacoum had been no longer detected after 2 months from the time of initial diagnosis, although bleeding tendency continued more than 100 days. Considering their result, serum brodifacoum level in the patient of our study might be decreased to undetectable range at the time of sample request, as superwarfarin level test had been requested about 100 days after initial symptom presentation by her physician.

Administration of vitamin K1 is the cornerstone of therapy in patients with superwarfarin intoxication. Oral vitamin K1 is preferred to intramuscular or intravenous injection, as it avoids hematoma formation and hypersensitivity reactions. An optimal dose and duration of vitamin K1 therapy has yet to be established (19). However, most previous studies support multiple, prolonged, and high dose vitamin K1 supplementation (1, 14-16, 19). As the half-life of vitamin K1 is 6 hr (7), multiple divided doses of vitamin K1 has the advantage of maintaining therapeutic effect. Prolonged use of high dose vitamin K1 is necessary as the half-life of superwarfarins is substantially long (9). Early tapering or discontinuation will result in repeat prolongation of PT and aPTT even after normal levels have been achieved (12). This repeat prolongation due to hasty discontinuation was observed in 6 of our patients (patient 1, 2, 3, 4, 6, and 8) and in previous reports (10, 14). A phased and prudent tapering of vitamin K1 with regular follow up is thus mandatory (15). In a case series of 9 patients in Taiwan (16), treatment duration ranged from 72 to 185 days. Table 2 shows the doses and durations of vitamin K1 therapy performed in our study and several previous reports. In a situation of emergency due to bleeding, transfusion of coagulation factors is effective, although the effect of this will be transient because of long half-life of superwarfarin. Urgent treatment with vitamin K1 and transfusion of coagulation factors based on clinical suspicion alone is justified because most detailed laboratory tests require several days to weeks.

Identifying the source of exposure is sometimes challenging in patients who deny ingestion of superwarfarin. After stabilization of symptoms, psychiatric interview should be recommended for patients in whom intentional administration is highly suspected as patient 2 of this study. We were unable to definitively identify the route of intoxication in 8 of the patients in this study. Environmental exposure was a possible cause in 3 patients (patients 4, 7, and 10) considering their occupations. As these patients had no symptoms or history of mental illness, and taking into account the potency, lipid solubility and long-half life of superwarfarin, we can cautiously consider transdermal absorption and inhalation as potential routes of their superwarfarin exposure. Such possibilities were highlighted in a previous report on 2 patients who worked in superwarfarin manufacture (3).

The incidence of superwarfarin intoxication should be surveyed nationwide in light of these recent cases. Supervision for rodenticide use and education of people who deal with rodenticides in their workplace are also necessary, along with further scientific research to achieve more accurate diagnosis and treatment of superwarfarin intoxication.

In conclusion, early suspicion with a prompt request of serum brodifacoum test and sufficient dose and duration of vitamin K1 therapy is necessary for effective treatment of superwarfarin intoxication. Further detailed investigation on the possibility and the actual condition of environmental exposure, and improving availability of the blood level test is mandatory.

REFERENCES

1. Chua JD, Friedenberg WR. Superwarfarin poisoning. Arch Intern Med 1998; 158: 1929-32.
2. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47: 911-1084.
3. Kim HY, Jeon HJ, Ko BS, Lee KH, Kim ST. Two cases of brodifacoum poisoning from inhalation route. Korean J Hematol 1996; 31: 473-9.
4. Lee JH, Kim H, Han HS, Lee K, Kim S. A case of superwarfarin intoxication without a definitive history of brodifacoum exposure. Korean J Hematol 2005; 44: 53-7.
5. Kim SY, Cho SY, Lee HJ, Suh JT, Oh SH, Lee WI, Park TS, Yoon HJ. Super-
warfarin intoxication of unknown etiology accompanying hemoperitoneum in a patient on fluconazole therapy. Ann Clin Lab Sci 2010; 40: 300-3.
6. Laurence D. Clinical pharmacology. Edinburgh, London and New York: Churchill Livingstone 1973; 234-5.
7. Park BK, Leck JB. A comparison of vitamin K antagonism by warfarin, difenacoum and brodifacoum in the rabbit. Biochem Pharmacol 1982; 31: 3635-9.
8. Lund M. Comparative effect of the three rodenticides warfarin, difenacoum and brodifacoum on eight rodent species in short feeding periods. J Hyg (Lond) 1981; 87: 101-7.
9. Weitzel JN, Sadowski JA, Furie BC, Moroose R, Kim H, Mount ME, Murphy MJ, Furie B. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood 1990; 76: 2555-9.
10. Chow EY, Haley LP, Vickars LM, Murphy MJ. A case of bromadiolone (superwarfarin) ingestion. CMAJ 1992; 147: 60-2.
11. Hui CH, Lie A, Lam CK, Bourke C. 'Superwarfarin' poisoning leading to prolonged coagulopathy. Forensic Sci Int 1996; 78: 13-8.
12. Katona B, Wason S. Superwarfarin poisoning. J Emerg Med 1989; 7: 627-31.
13. Park BK, Scott AK, Wilson AC, Haynes BP, Breckenridge AM. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol 1984; 18: 655-62.
14. Pavlu J, Harrington DJ, Voong K, Savidge GF, Jan-Mohamed R, Kaczmarski R. Superwarfarin poisoning. Lancet 2005; 365: 626.
15. Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol 2007; 82: 656-60.
16. Wu YF, Chang CS, Chung CY, Lin HY, Wang CC, Shen MC. Superwarfarin intoxication: hematuria is a major clinical manifestation. Int J Hematol 2009; 90: 170-3.
17. Zupancić-Salek S, Kovacević-Metelko J, Radman I. Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII. Blood Coagul Fibrinolysis 2005; 16: 239-44.
18. Jin MC, OuYang XK, Chen XH. High-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry for the determination of flocoumafen and brodifacoum in whole blood. J Appl Toxicol 2007; 27: 18-24.
19. Bruno GR, Howland MA, McMeeking A, Hoffman RS. Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med 2000; 36: 262-7.